Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Metadata referenced GT Biopharma, but filing text confirms OXIS International, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2011
Business Overview: OXIS is engaged in the research, development, and sale of products counteracting oxidative stress and inflammation, primarily focusing on L-Ergothioneine ("ERGO"). The company operates as a smaller reporting company with a single reportable segment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Six Months Ended June 30, 2010 |
|---|---|---|
| Total Revenue | $21,000 | $0 |
| Net Loss | $(2,585,000) | $(1,700,000) |
| Operating Expenses | $2,320,000 | $1,316,000 |
| Interest Expense | $348,000 | $384,000 |
| Cash and Cash Equivalents (End of Period) | $89,000 | $571,000 |
| Total Current Liabilities | $5,798,000 | $5,654,000 |
| Working Capital Deficit | $(5,570,000) | $(5,469,000) |
| Accumulated Deficit | $(82,680,000) | $(80,095,000) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $21,000 in product revenue for the six months ended June 30, 2011, compared to zero in the prior year, driven by a direct mail test market for ErgoFlex initiated in late 2010. However, costs exceeded revenues due to high start-up manufacturing costs.
- Expense Increase: Selling, general, and administrative (SG&A) expenses increased by $1,049,000 (86%) year-over-year. This was primarily due to increased non-cash compensation ($1,597,000 for services), overhead, and shareholder relations expenses.
- Debt and Equity Activity: The company issued significant shares of common stock for debt conversion ($780,100 of debt converted in Q2 2011) and services ($1,500,000 value in Q2 2011). Common shares outstanding increased from ~149.6 million to ~209.5 million.
- Liquidity Deterioration: Cash balances decreased by $482,000 during the six-month period, leaving only $89,000 in cash against nearly $5.8 million in current liabilities.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that the current rate of cash usage raises substantial doubt about the company's ability to continue as a going concern. The company requires additional equity or debt financing to sustain operations.
- Capital Needs: Funds from previous financings are depleted. The company plans to raise capital to fund a new marketing joint venture (Engage:BDR) requiring up to $1.5 million and a new joint venture (Ergo ARDS, LLC) for ARDS treatment development.
- Debt Defaults: The company is in default on convertible debentures issued in 2006 due to missed monthly redemption payments. While a Standstill and Forbearance Agreement exists with a major creditor (Bristol Investment Fund), the company remains obligated for deficiency balances.
- Management Changes: Anthony Cataldo resigned as CEO effective June 1, 2011, remaining as Chairman. New board members were appointed in June 2011.
- Future Revenue: Management anticipates significant revenue increases in 2011 if adequately capitalized, relying on the Engage:BDR joint venture for online marketing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $89,000 cash balance against the $5.8 million current liability obligation and ongoing burn rate.
- Financing Status: Confirm the status of the planned $500,000 June 2011 financing and any subsequent equity/debt raises required to fund the $1.5 million joint venture commitment.
- Debt Resolution: Review the terms of the Standstill Agreement with Bristol Investment Fund and the risk of asset foreclosure or acceleration of debt.
- Dilution Risk: Assess the impact of outstanding warrants (~79 million) and convertible debentures on existing shareholders, noting the recent increase in authorized shares to 600 million.
- Revenue Sustainability: Evaluate whether the $21,000 in test market revenue is scalable or merely a one-time anomaly given the lack of active marketing in prior periods.